Tissue Regenix Group has a quick ratio of 0.77. It indicates that the company cannot currently fully pay back its current liabilities.
The historical rank and industry rank for Tissue Regenix Group's Quick Ratio or its related term are showing as below:
FRA:LSW'
s Quick Ratio Range Over the Past 10 Years
Min: 0.77 Med: 3.17 Max: 42.96
Current: 0.77
During the past 13 years, Tissue Regenix Group's highest Quick Ratio was 42.96. The lowest was 0.77. And the median was 3.17.
FRA:LSW's Quick Ratio is not ranked
in the Biotechnology industry.
Industry Median: 3.6
vs FRA:LSW: 0.77
Tissue Regenix Group (FRA:LSW) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Tissue Regenix Group Quick Ratio Related Terms
Tissue Regenix Group Quick Ratio Historical Data
* Premium members only.
The historical data trend for Tissue Regenix Group's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:LSW vs VRTX, REGN, ALNY: Quick Ratio Comparison
For the Biotechnology subindustry, Tissue Regenix Group's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tissue Regenix Group Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Tissue Regenix Group's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Tissue Regenix Group's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Tissue Regenix Group's Quick Ratio for the fiscal year that ended in Dec. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tissue Regenix Group (FRA:LSW) has a Quick Ratio of 0.77 as of Jun. 2025. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Tissue Regenix Group and its competitors. This is 76% below median its historical median of 3.17. Over the past decade, Tissue Regenix Group's Quick Ratio has ranged from 0.77 to 42.96.
Is Tissue Regenix Group's Quick Ratio too high?
Tissue Regenix Group's current Quick Ratio of 0.77 is 76% below median its 10-year median of 3.17. Over the past 10 years, this metric has ranged from a low of 0.77 to a high of 42.96. The Biotechnology industry median Quick Ratio is 3.60. Tissue Regenix Group's value of 0.77 is 78.6% below this industry median. Overall, Tissue Regenix Group has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Tissue Regenix Group's Quick Ratio compare to VRTX and REGN?
Tissue Regenix Group's Quick Ratio of 0.77 can be compared against companies in the Biotechnology industry. The industry median Quick Ratio is 3.60. Tissue Regenix Group's value of 0.77 is 78.6% below this benchmark. Historically, Tissue Regenix Group's own Quick Ratio has ranged from 0.77 to 42.96 over the past decade. While the company's 10-year median is 3.17 vs. the industry median of 3.60, Tissue Regenix Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,416 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tissue Regenix Group's current Quick Ratio of 0.77 is 78.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Tissue Regenix Group and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tissue Regenix Group's current Quick Ratio is 0.77, which is 76% below median its own 10-year median of 3.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tissue Regenix Group stock overvalued right now?
Tissue Regenix Group (FRA:LSW) has a current Quick Ratio of 0.77. The stock's GF Value™ is €0.84, compared to a current price of €0.07 — trading 91.7% below its estimated fair value. The current Quick Ratio is 0.77, which is 76% below median its 10-year median of 3.17 and 78.6% below the Biotechnology industry median of 3.60. Tissue Regenix Group's overall GF Score™ is 10/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Tissue Regenix Group (FRA:LSW), the current Quick Ratio is 0.77 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tissue Regenix Group (FRA:LSW) Overvalued in 2026?
Based on GuruFocus' analysis, Tissue Regenix Group stock appears to be undervalued.
The current stock price of €0.07 is trading 91.7% below its estimated GF Value™ of €0.84.
Key valuation signals for FRA:LSW:
Quick Ratio: 0.77 (76% below median its 10-year median of 3.17)
GF Value™: €0.84 vs. price of €0.07 (91.7% below fair value)
Industry Position: 78.6% below the Biotechnology median
No single metric tells the full story. See the FRA:LSW stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tissue Regenix Group PLC is a pioneering medical technology company engaged in the development of regenerative products. The company incorporates dCELL and BioRinse technology, which helps to address complex and varying clinical needs. Its product portfolio includes Biosurgery, Orthopaedics, and Dental. The company has operations around the world, with special emphasis in the United States.
10GF Score
Get the complete analysis for FRA:LSW
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:LSW has been successfully added to your 
